Stock Events

Eterna Therapeutics 

$2.15
23
+$0.02+0.94% Friday 20:00

Statistics

Day High
2.34
Day Low
2.06
52W High
2.96
52W Low
0.84
Volume
13,268
Avg. Volume
8,256
Mkt Cap
11.63M
P/E Ratio
-1.42
Dividend Yield
-
Dividend
-

Earnings

14MayConfirmed
Q1 2022
Q2 2022
Q3 2022
Q4 2022
Q3 2023
Q4 2023
Q1 2024
-3.4
-2.61
-1.82
-1.03
Expected EPS
N/A
Actual EPS
-1.23

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ERNA. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
CRISPR Therapeutics
CRSP
Mkt Cap4.92B
CRISPR Therapeutics is a leader in the development of gene-based therapies, directly competing with Eterna's focus on mRNA and gene editing technologies.
Editas Medicine
EDIT
Mkt Cap455.6M
Editas Medicine operates in the gene editing space, making it a direct competitor to Eterna Therapeutics in the development of gene therapy solutions.
Intellia Therapeutics
NTLA
Mkt Cap2.49B
Intellia Therapeutics is another key player in the CRISPR/Cas9 gene editing technology, competing in the same space as Eterna Therapeutics.
Beam Therapeutics
BEAM
Mkt Cap2.21B
Beam Therapeutics uses base editing, a form of gene editing, positioning it as a competitor in the gene therapy market alongside Eterna Therapeutics.
Sangamo Therapeutics
SGMO
Mkt Cap94.38M
Sangamo Therapeutics focuses on genomic medicine, including gene editing and gene therapy, competing with Eterna in the development of genetic treatments.
Alnylam Pharmaceuticals
ALNY
Mkt Cap32.95B
Alnylam Pharmaceuticals is a leader in RNAi (RNA interference) therapeutics, competing with Eterna's focus on mRNA therapies.
Ionis Pharmaceuticals
IONS
Mkt Cap7.01B
Ionis Pharmaceuticals specializes in RNA-targeted drug discovery and development, making it a competitor in the RNA space with Eterna.
Biomarin Pharmaceutical
BMRN
Mkt Cap16.14B
BioMarin Pharmaceutical focuses on enzyme replacement therapies, which can be seen as complementary or competitive to gene therapies offered by Eterna.
Vertex Pharmaceuticals
VRTX
Mkt Cap126.12B
Vertex Pharmaceuticals, with its focus on treating genetic diseases, competes in the broader market for genetic therapies that Eterna is also targeting.
Bluebird bio
BLUE
Mkt Cap133.39M
bluebird bio focuses on gene therapy for genetic diseases and cancer, directly competing with Eterna Therapeutics in the gene therapy space.

About

Brooklyn ImmunoTherapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing therapies to treat patients with cancer. Its advanced program is IRX-2 that is in a Phase 2b clinical trial in patients with squamous cell cancer of the head and neck. The company also develops therapies using gene-editing and cell therapy technology for the treatment of oncology, blood disorder, and monogenic disease. Brooklyn ImmunoTherapeutics, Inc. is based in Brooklyn, New York.
Show more...
CEO
Employees
8
Country
US
ISIN
US1140822099

Listings